AI Article Synopsis
- - A study was conducted to assess the effectiveness of shared decision-making (SDM) in helping adults at risk for diabetes by offering lifestyle changes, metformin, or both in 20 primary care locations.
- - Results showed that participants in the SDM group maintained greater weight loss compared to control participants at both the 24-month (-3.1 lb) and 36-month (-2.7 lb) marks, with those choosing both options achieving a sustained 36-month weight loss of -4.1 lb.
- - There was no significant difference in the rate of new diabetes cases between the SDM participants (15%) and the control group (14%), suggesting the focus on weight loss did not reduce diabetes incidence substantially.
Article Abstract
Objective: We conducted a cluster-randomized, shared decision-making (SDM) trial offering lifestyle change, metformin, or both options, to adults at risk for diabetes in a primary care network (n = 20 practices).
Research Design And Methods: We used propensity score matching to identify control patients and used electronic health record data to compare weight loss at 24 and 36 months of follow-up and diabetes incidence at 36 months of follow-up.
Results: In adjusted post hoc analyses, SDM participants (n = 489) maintained modestly greater 24-month weight loss of -3.1 lb and 36-month weight loss of -2.7 lb versus controls (n = 1,430, both comparisons P < 0.001). SDM participants who chose both lifestyle change and metformin sustained weight loss at 36 months of -4.1 lb (P < 0.001 vs. controls). We found no differences in incident diabetes (15% of SDM participants, 14% of control participants; P = 0.64).
Conclusions: This is one of the first studies to demonstrate weight loss maintenance up to 36 months after diabetes prevention SDM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10698217 | PMC |
| http://dx.doi.org/10.2337/dc23-0829 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy.
Obstet Gynecol
January 2025
Department of Obstetrics and Gynecology and the Division of Maternal Fetal Medicine, University of Kansas School of Medicine, Kansas City, Kansas.
Obesity is a chronic condition that causes significant morbidity and mortality in people in the United States and around the world. Traditional means of weight loss include diet, exercise, behavioral modifications, and surgery. New weight loss medications, glucagon-like peptide-1 receptor agonists, are revolutionizing the management of weight loss but have implications for fertility and pregnancy.
View Article and Find Full Text PDFSemaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis.
Pharmacoecon Open
January 2025
Department of Public Health Policy, School of Public Health, University of West Attica, 196 Alexandras Avenue, 115 21, Athens, Greece.
Background: Obesity is a global health issue with significant economic implications for health systems. Pharmacotherapy, including semaglutide 2.4 mg and liraglutide 3 mg, offers a treatment option for weight management; however, its cost-effectiveness requires evaluation.
View Article and Find Full Text PDFImpact of a community-based lifestyle intervention with initial sedentary reduction or physical activity increasing goals on self-reported health-related quality of life.
Transl Behav Med
January 2025
University of Pittsburgh School of Public Health, Department of Epidemiology, Pittsburgh, PA, USA.
Background: In previous efforts, health-related quality of life (HRQoL) improved for individuals at high risk of type 2 diabetes and cardiovascular disease after participation in community-based lifestyle interventions (LI) with a moderate-to-vigorous physical activity (MVPA) movement goal.
Purpose: It is unknown whether HRQoL improves with LI when the primary movement goal is to reduce sedentary behavior. HRQoL changes were examined among adults with overweight and prediabetes and/or metabolic syndrome randomized to a 12-month Diabetes Prevention Program-based Group Lifestyle Balance (DPP-GLB) community LI work with goals of weight-loss and either increasing MVPA (DPP-GLB) or reducing sedentary time (GLB-SED).
Development and Evaluation of a New Gastroenteritis Clinical Severity Score for Children Aged Under 5.
Acta Paediatr
January 2025
INSERM, Clinical Research Department, University Hospital of Nantes, Nantes, France.
Aim: To develop and internally validate a new severity score to more accurately assess the clinical severity forms of acute gastroenteritis (AGE) in children from birth to age 5 years.
Methods: We included children consulting for AGE in the emergency department of the University Hospital of Nantes (March 2017-June 2019). We developed and evaluated a new predictive score (GASTROVIM score) using the classification and regression trees.
Autoantibodies, Oxidative Stress, and Nutritional State in Anorexia Nervosa.
Antibodies (Basel)
December 2024
IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
: Anorexia nervosa (AN) is a complex psychiatric disorder characterized by an extreme fear of gaining weight, leading to severe calorie restriction and weight loss. Beyond its psychiatric challenges, AN has significant physical consequences affecting multiple organ systems. Recent research has increasingly focused on the interplay between autoantibodies, oxidative stress, and nutritional state in this condition.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!